Citations

Showing 10 of 108094 citations.

Epithelial‐to‐mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity
Hong, Deli , Fritz, Andrew J. , Zaidi, Sayyed K. , Wijnen, André J. van , Nickerson, Jeffrey A. , Imbalzano, Anthony N. , Lian, Jane B. , Stein, Janet L. , Stein, Gary S. , van Wijnen, Andre J , Stein, Gary S

Mayo Clinic

Journal of Cellular Physiology | July 3, 2018 | Volume: 233 | Issue: 12 | Pages: 9136-9144

10.1002/jcp.26847 | PMID 29968906 Get It

Breast cancer is the most common cancer in women, and accounts for ~30% of new cancer cases and 15% of cancer‐related deaths. Tumor relapse and metastasis are primary factors contributing to breast cancer‐related deaths. Therefore, the challenge for breast cancer treatment is to sustain remission. A driving force behind tumor relapse is breast cancer heterogeneity (both intertumor, between different patients, and intratumor, within the same tumor). Understanding breast cancer heterogeneity is necessary to develop preventive interventions and targeted therapies. A recently emerging concept is that intratumor heterogeneity is driven by cancer stem cells (CSCs) that are capable of giving rise to a multitude of different cells within a tumor. Studies have highlighted linkage of CSC formation with epithelial‐to‐mesenchymal transition (EMT). In this review, we summarize the current understanding of breast cancer heterogeneity, links between EMT and CSCs, regulation of EMT by Runx transcription factors, and potential therapeutic strategies targeting these processes.
Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
Calligaris, David, Feathers, Ryan W. , Vaubel, Rachael A. , Meaux, Isabelle, Mladek, Ann C. , Parrish, Karen E. , Barrière, Cédric, Debüssche, Laurent , Watters, James , Tian, Shulan , Decker, Paul A. , Eckel‐Passow, Jeanette E. , Kitange, Gaspar J. , Johnson, Aaron J. , Anastasiadis, Panos Z. , Agar, Nathalie Y.R. , Elmquist, William F. , Vaubel, Rachael A , Parney, Ian F , Agar, Nathalie Y R , Kim, Minjee , Daniel, J. , Zhang, Shuangling , Jin, Fang , Decker, Paul A. , Johnson, Aaron J. , Parney, Ian F. , Sarkaria, Jann N. , Mladek, Ann C

Mayo Clinic

Molecular Cancer Therapeutics | July 3, 2018 | Volume: 17 | Issue: 9 | Pages: 1893-1901

10.1158/1535-7163.mct-17-0600 | PMID 29970480 Get It

Abstract Controversy exists surrounding whether heterogeneous disruption of the blood–brain barrier (BBB), as seen in glioblastoma (GBM), leads to adequate drug delivery sufficient for efficacy in GBM. This question is especially important when using potent, targeted agents that have a poor penetration across an intact BBB. Efficacy of the murine double minute-2 (MDM2) inhibitor SAR405838 was tested in patient-derived xenograft (PDX) models of GBM. In vitro efficacy of SAR405838 was evaluated in PDX models with varying MDM2 expression and those with high (GBM108) and low (GBM102) expression were evaluated for flank and orthotopic efficacy. BBB permeability, evaluated using TexasRed-3 kDa dextran, was significantly increased in GBM108 through VEGFA overexpression. Drug delivery, MRI, and orthotopic survival were compared between BBB-intact (GBM108-vector) and BBB-disrupted (GBM108-VEGFA) models. MDM2-amplified PDX lines with high MDM2 expression were sensitive to SAR405838 in comparison with MDM2 control lines in both in vitro and heterotopic models. In contrast with profound efficacy observed in flank xenografts, SAR405838 was ineffective in orthotopic tumors. Although both GBM108-vector and GBM108-VEGFA readily imaged on MRI following gadolinium contrast administration, GBM108-VEGFA tumors had a significantly enhanced drug and gadolinium accumulation, as determined by MALDI-MSI. Enhanced drug delivery in GBM108-VEGFA translated into a marked improvement in orthotopic efficacy. This study clearly shows that limited drug distribution across a partially intact BBB may limit the efficacy of targeted agents in GBM. Brain penetration of targeted agents is a critical consideration in any precision medicine strategy for GBM. Mol Cancer Ther; 17(9); 1893–901. ©2018 AACR.
Extensive clinical experience: Hypothalamic‐pituitary‐adrenal axis recovery after adrenalectomy for corticotropin‐independent cortisol excess
Hurtado, Maria D. , Cortes, Tiffany , Natt, Neena, Hurtado, Maria Daniela , Young, William F. , Bancos, Irina

Mayo Clinic

Clinical Endocrinology | July 3, 2018 | Volume: 89 | Issue: 6 | Pages: 721-733

10.1111/cen.13803 | PMID 29968420 Get It

Summary Objective To identify predictors of hypothalamic‐pituitary‐adrenal ( HPA ) axis recovery interval and severity of glucocorticoid withdrawal symptoms ( GWS ) in patients undergoing adrenalectomy for corticotropin‐independent cortisol excess. Design This is a retrospective study of patients with mild autonomous cortisol excess ( MACE ), moderate and severe Cushing syndrome ( CS ) who developed adrenal insufficiency after unilateral adrenalectomy between 1998 and 2017. Results Adrenalectomy was performed in 81 patients (79% women, median age 52 years [ IQR 42‐62]). HPA axis recovery occurred at a median of 4.3 months ( IQR 1.6‐11.4) after adrenalectomy (severe CS vs moderate CS vs MACE : median 11.4 vs 2.8 vs 2.1 months, P < 0.01). Main predictors of HPA axis recovery interval included: preoperative serum cortisol concentration after 1‐mg overnight dexamethasone suppression test >10 μg/ dL or >276 nmol/L (9.7 vs 1.3 months if cortisol ≤10 μg/ dL or ≤276 nmol/L, P < 0.01); body mass index (for every 3 kg/m 2 decrease, glucocorticoid taper increased by 1 month, P < 0.05); age <45 (11.4 vs 2.3 months if ≥45 years, P < 0.05); duration of symptoms prior to diagnosis >1 year (11.4 vs 2.8 months if ≤1 year); moon facies (11.4 vs 2.2 months if no rounding of the face); and myopathy (13.1 vs 2.7 months if no myopathy, P < 0.05). Patients with severe CS had a higher incidence of GWS compared to patients with MACE (66.7% vs 40.0%, P < 0.05) with a median of 1 and 0 events/patient, respectively. Conclusions The HPA axis recovery interval was the longest for patients with severe CS . Surprisingly, patients with moderate CS recovered their HPA axis as quickly as those with MACE . Glucocorticoid withdrawal symptoms were observed in all groups, with more events in patients with severe CS . This study emphasizes the need to counsel patients on expectations for HPA axis recovery and address intervention for GWS based on individual preoperative parameters.
Risk factors for pleural effusion recurrence in patients with malignancy
Grosu, Horiana B. , Molina, Sofía, Casal, Roberto F. , Song, Juhee , Diaz‐Mendoza, Javier , Reddy, Chakravarthy, Yarmus, Lonny , Schiavo, Dante , Simoff, Michael , Johnstun, Jared, Raid, A.H. Zedan, Feller‐Kopman, David , Sahetya, Sarina K. , Foley, Finbar, Maldonado, Fabien , Noor, Laila , Miller, Russell , Mudambi, Lakshmi, Saettele, Timothy , Vial, Macarena R. , Eapen, Gerogie A., Ost, David E. , Garcia, Sofia Molina , Casal, Roberto , Yarmus, Lonny , Vial-Rodriguez, Macarena , Ost, David E , Li, Liang , Lee, Hans C. , Tian, Xin , Molina Garcia, Sofia

Mayo Clinic

Respirology | July 2, 2018 | Volume: 24 | Issue: 1 | Pages: 76-82

10.1111/resp.13362 | PMID 29966171 Get It

ABSTRACTBackground and objectiveThe main purpose of treatment in patients with malignant pleural effusion (MPE) is symptom palliation. Currently, patients undergo repeat thoracenteses prior to receiving a definitive procedure as clinicians are not aware of the risk factors associated with fluid recurrence. The primary objective of this study was to identify risk factors associated with recurrent symptomatic MPE.MethodsRetrospective multicentre cohort study of patients who underwent first thoracentesis was performed. The primary outcome was time to fluid recurrence requiring intervention in patients with evidence of metastatic disease. We used a cause‐specific hazard model to identify risk factors associated with fluid recurrence. We also developed a predictive model, utilizing Fine–Gray subdistribution hazard model, and externally validated the model.ResultsA total of 988 patients with diagnosed metastatic disease were included. Cumulative incidence of recurrence was high with 30% of patients recurring by day 15. On multivariate analysis, size of the effusion on chest X‐ray (up to the top of the cardiac silhouette (hazard ratio (HR): 1.84, 95% CI: 1.21–2.80, P = 0.004) and above the cardiac silhouette (HR: 2.22, 95% CI: 1.43–3.46, P = 0.0004)), larger amount of pleural fluid drained (HR: 1.06, 95% CI: 1.04–1.07, P < 0.0001) and higher pleural fluid LDH (HR: 1.008, 95% CI: 1.004–1.011, P < 0.0001) were associated with increased hazard of recurrence. Negative cytology (HR: 0.52, 95% CI: 0.43–0.64, P < 0.0001) was associated with decreased hazard of recurrence. The model had low prediction accuracy.ConclusionPleural effusion size, amount of pleural fluid drained, LDH and pleural fluid cytology were found to be risk factors for recurrence.
Decision-Making Factors for Ulnar Nerve Transposition in Cubital Tunnel Surgery
DeGeorge, Brent R. , Kakar, Sanjeev

Mayo Clinic

Journal of Wrist Surgery | July 2, 2018 | Volume: 08 | Issue: 02 | Pages: 168-174

10.1055/s-0038-1665548 | PMID 30941260 Get It

Background We designed a survey to ascertain the current perspectives of hand surgeons on the evaluation and management of ulnar nerve instability at the elbow. The secondary aim was to assess the concordance of hand surgeons on definitions of the terms “subluxated” and “dislocated” for classification of ulnar nerve instability. Methods A questionnaire, including demographic practice variables, cubital tunnel practice patterns, preoperative imaging and electrodiagnostic evaluation, and a series of standardized intraoperative photographs of ulnar nerve instability at the elbow were developed and distributed to the current American Society for Surgery of the Hand (ASSH) membership. Results A total of 690 (26.8%) members completed the survey; 84.2% of respondents indicated that they evaluate for ulnar nerve instability preoperatively with clinical examination, whereas only 6.1% indicated they routinely obtained dynamic ultrasound. Respondents indicated that the factors most strongly influencing their decision to proceed with anterior transposition of the ulnar nerve were subluxation on physical examination (89.6%), history consistent with ulnar nerve subluxation (85.8%), and muscle atrophy (43.2%). On review of clinical photographs, respondents demonstrated varying degrees of agreement on the terms “subluxated” or “dislocated” and recommendations for ulnar nerve transposition at intermediate degrees of ulnar nerve instability. Conclusion ASSH members routinely evaluate for ulnar nerve instability with history and clinical examination without uniform use of preoperative ultrasound, and nearly half of the time the decision to transpose the ulnar nerve is made intraoperatively. Definitions for the degree of ulnar nerve instability at the elbow are not uniformly agreed upon, and further development of a classification system may be warranted to standardize treatment.
Venous Thromboembolism (VTE) Incidence and VTE-Associated Survival among Olmsted County Residents of Local Nursing Homes
Petterson, Tanya M. , Emerson, Jane A., Bailey, Kent R. , Ashrani, Aneel A. , Heit, John A. , Leibson, Cynthia L., Smith, Carin Y.

Mayo Clinic

Thrombosis and Haemostasis | July 2, 2018 | Volume: 118 | Issue: 07 | Pages: 1316-1328

10.1055/s-0038-1660436 | PMID 29966167 Get It

AbstractNursing home (NH) residency is an independent risk factor for venous thromboembolism (VTE), but the VTE burden within the NH population is uncertain. This study estimates VTE incidence and VTE-associated mortality among NH residents. We identified all NH residents in any NH in Olmsted County, Minnesota, United States, 1 October 1998 to 31 December 2005 and all first lifetime VTE among county residents to estimate VTE incidence while resident of local NHs (NHVTE), using Centers for Medicare and Medicaid Services Minimum Data Set and Rochester Epidemiology Project resources. We tested associations between NHVTE and age, sex and time since each NH admission using Poisson modelling. Additionally, we tested incident NHVTE as a potential predictor of survival using Cox proportional hazards, adjusting for age, sex and NH residency. Between 1 October 1998 and 31 December 2005, 3,465 Olmsted County residents with ≥1 admission to a local NH, contributed 4,762 NH stays. Of the 3,465 NH residents, 111 experienced incident NHVTE (2.3% of all eligible stays), for an overall rate of 3,653/100,000 NH person-years (NH-PY). VTE incidence was inversely associated with time since each NH admission, and was highest in the first 7 days after each NH admission (18,764/100,000 NH-PY). The adjusted hazard of death for incident NHVTE was 1.90 (95% confidence interval [CI]: 1.38–2.62). In conclusion, VTE incidence among NH residents was nearly 30-fold higher than published incidence rates for the general Olmsted County population. VTE incidence was highest within 7 days after NH admission, and NHVTE was associated with significantly reduced survival. These data can inform future research and construction of clinical trials regarding short-term prophylaxis.
Physiological Glucocorticoid Replacement in Adrenal Insufficiency: Does It Fix the Broken Clock?
Brown, Matthew R, Matveyenko, Aleksey V. , Brown, Matthew , Brown, Matthew R , Brown, Matthew R

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 2, 2018 | Volume: 103 | Issue: 9 | Pages: 3511-3513

10.1210/jc.2018-01245 | PMID 29982538 Get It

Heart Failure Epidemic
Roger, Véronique L.

Mayo Clinic

Circulation | July 2, 2018 | Volume: 138 | Issue: 1 | Pages: 25-28

10.1161/circulationaha.118.028478 | PMID 29967230 Get It

Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma
Li, Qian , Hou, Xiaonan , Weroha, S. John , Kalli, Kimberly R., Cunningham, Julie M. , Lawrenson, Kate , Gayther, Simon A. , Goode, Ellen L. , Cunningham, Julie M , Lawrenson, Kate , Fridley, Brooke L. , Dai, Junqiang , Raghavan, Rama , Winham, Stacey J. , Wang, Chen

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 2, 2018 | Volume: 27 | Issue: 9 | Pages: 1101-1109

10.1158/1055-9965.epi-17-0728 | PMID 29967001 Get It

Abstract Background: Endometrioid carcinoma (EC) and clear cell carcinoma (CC) histotypes of epithelial ovarian cancer are understudied compared with the more common high-grade serous carcinomas (HGSC). We therefore sought to characterize EC and CC transcriptomes in relation to HGSC. Methods: Following bioinformatics processing and gene abundance normalization, differential expression analysis of RNA sequence data collected on fresh-frozen tumors was completed with nonparametric statistical analysis methods (55 ECs, 19 CCs, 112 HGSCs). Association of gene expression with progression-free survival (PFS) was completed with Cox proportional hazards models. Eight additional multi-histotype expression array datasets (N = 852 patients) were used for replication. Results: In the discovery set, tumors generally clustered together by histotype. Thirty-two protein-coding genes were differentially expressed across histotype (P &lt; 1 × 10−10) and showed similar associations in replication datasets, including MAP2K6, KIAA1324, CDH1, ENTPD5, LAMB1, and DRAM1. Nine genes associated with PFS (P &lt; 0.0001) showed similar associations in replication datasets. In particular, we observed shorter PFS time for CC and EC patients with high gene expression for CCNB2, CORO2A, CSNK1G1, FRMD8, LIN54, LINC00664, PDK1, and PEX6, whereas, the converse was observed for HGSC patients. Conclusions: The results suggest important histotype differences that may aid in the development of treatment options, particularly those for patients with EC or CC. Impact: We present replicated findings on transcriptomic differences and how they relate to clinical outcome for two of the rarer ovarian cancer histotypes of EC and CC, along with comparison with the common histotype of HGSC. Cancer Epidemiol Biomarkers Prev; 27(9); 1101–9. ©2018 AACR.